Table 1a.
Vancomycin population pharmacokinetic parameter estimates using a linear model relating postmenstrual age (PMA) to clearance (CL)
| Parameter | Estimate | BSV | BOV | %SE |
|---|---|---|---|---|
| CLstd (lh−170kg−1) at 40weeks PMA and RF=1 | 2.19 | 0.187 | 0.122 | 15.3 |
| Vstd (l70kg−1) | 39.0 | 0.194 | – | 2.5 |
| SLPCL (1week−1) | 0.0216 | – | – | 17.2 |
| Fventilation (on CL) | 0.942 | – | – | 3.5 |
| Finotrope (on V) | 1.17 | – | – | 9.9 |
| Kage | 0.0096 | – | – | 40.4 |
| Residual unidentified variability additive | 1.4mgl−1 | – | – | 30.6 |
| proportional | 0.23% | – | – | 10.7 |
BSV and BOV are the between-subject and between-occasion variability expressed as the square root of their variance; SE is the standard error of the structural estimate. V = Vstd × (Wt/70) × Finotrope × Inot l. CL = CLstd × (Wt/70)0.75 × [1+SLPCL × (PMA−40)] × RF × Fventilation × Vent)lh−1 where Vstd and CLstd are the population estimates for V and CL, respectively, standardized to a 70-kg person using allometric models; PMA is the postmenstrual age in weeks; SLPCL is the factor relating PMA to developmental changes in CL; Finotrope and Fventilation are scaling factors applied for the use of inotropes (Inot) or positive pressure artificial ventilation (Vent); Inot and Vent have a value of 1 if present and 0 if absent. The calculation of renal function (RF) is explained in the text.